Spectrum Pharmaceuticals, Inc. Enters Into $150 Million At Market Issuance Sales Agreement

Spectrum Pharmaceuticals, Inc.

Represented Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) in connection with an At Market Issuance Sales Agreement with FBR Capital Markets & Co., MLV & Co. LLC, and H.C. Wainwright & Co., LLC, in connection with the offering, issuance and sale of up to $150 million of Spectrum’s Common Stock under the previously-filed shelf registration statement on Form S-3, for the offering of up to $250 million of common stock, preferred stock, debt securities, warrants for debt or equity securities and units (the “Shelf Registration Statement”). In July of this year, Spectrum successfully completed its offering of Common Stock pursuant to the $100 Million At Market Issuance Sales Agreement dated December 23, 2015, under the same Shelf Registration Statement.

Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations, with a primary focus on oncology and hematology. As disclosed in the Shelf Registration Statement, Spectrum intends to use the net proceeds from the sale of the securities for general corporate purposes, including, sales and marketing activities, clinical development, making acquisitions of assets, businesses, companies or securities, capital expenditures and for working capital.

The Newport Beach-based team representing Spectrum included Marc AlcserJason Lee and Matthew Brodsky.